CommercialCoverageHigh impact
Cardiovascular Disease Risk Tests (CPB 0381, reviewed 2026-06-29)
Aetna·Cardiology, Internal Medicine, Family Medicine +2 more·Medical Policy
Effective date
Jun 29, 2026
We identified it
Aug 15, 2026
Summary
Aetna updated its medical policy on cardiovascular disease risk testing (CPB 0381), effective June 29, 2026. The policy clarifies which tests are medically necessary (e.g., ApoB for patients on lipid-lowering therapy who've met LDL goals, one-time Lp(a) screening for all adults 19+, hsCRP for borderline ASCVD risk) and designates numerous other tests as experimental/investigational, including repeat Lp(a) testing, cardiac stress testing in asymptomatic low-risk patients, and over 100 specific biomarker panels and genetic tests. Billing teams must update prior authorization rules and claim denial protocols accordingly.
Action Required
Effective immediately (policy dated 2026-06-29): Billing and authorization teams must update the system to reflect Aetna's new coverage decisions. (1) MEDICALLY NECESSARY TESTS - Update claim processing to ALLOW coverage without prior auth when criteria are met: ApoB testing for patients on stable lipid-lowering therapy who have achieved LDL-C or non-HDL-C goals AND have high-risk indications (ASCVD, CKM syndrome, Type 2 diabetes, elevated triglycerides); one-time Lp(a) testing for all adults 19+; hsCRP testing for adults 30-79 with borderline 10-year ASCVD risk (3-4.9%) not on statins. (2) EXPERIMENTAL/NOT COVERED TESTS - Update system to DENY or require prior authorization denial for: repeat/serial ApoB measurements; repeat Lp(a) testing; hsCRP for general population screening, asymptomatic individuals, or therapy monitoring; cardiac stress testing/stress echo in asymptomatic low-risk individuals; carotid intima-media thickness; arterial elasticity measurements; peripheral arterial tonometry; screening ultrasound of extremity arteries/veins; and the 100+ listed biomarker and genetic tests (including Lp-PLA2, MPO, TMAO, MTHFR testing, VAP, Corus CAD, etc.). (3) PROVIDER COMMUNICATION - Notify in-house cardiology, internal medicine, and primary care providers of the new criteria; provide a summary of covered vs. non-covered tests. (4) CLAIM EDITS - Configure system edits to flag claims for the 100+ experimental tests and route to denial review; add logic to require documentation of medical necessity criteria for ApoB (evidence of stable lipid therapy + achieved LDL/non-HDL goals + high-risk indication) and hsCRP (10-year ASCVD risk calculation documentation). (5) APPEALS PREPARATION - Anticipate appeals from providers ordering experimental tests; establish response template citing CPB 0381. Failure to implement these edits will result in inappropriate claim payment for experimental tests and incorrect denials of medically necessary tests.